Tango Therapeutics报告2025年业绩优于预期，现金和股价均受吉利德交易和肿瘤学进展推动。 Tango Therapeutics reports better-than-expected 2025 results, boosting cash and shares, driven by Gilead deal and oncology progress.

探戈治疗机构报告说,2025年的第四季度结果比预期的要强,净损失减少,合作收入增加,主要来自其Gilead伙伴关系。 Tango Therapeutics reported stronger-than-expected fourth-quarter results for 2025, with a narrowed net loss and increased collaboration revenue, primarily from its Gilead partnership. 该公司的现金头寸达到3.431亿美元,将其跑道延长到2028年。 The company’s cash position reached $343.1 million, extending its runway into 2028. 股份猛增36.3%至16.83美元,标志着其最好的单日收益,这得益于分析师升级、机构采购和肿瘤管道的进展,包括其主要候选者vopimetostat。 Shares surged 36.3% to $16.83, marking their best single-day gain, fueled by analyst upgrades, institutional buying, and progress in its oncology pipeline, including its lead candidate vopimetostat. 尽管不断亏损,但投资者信心因财政实力和2026年即将到来的临床里程碑而提高。 Despite ongoing losses, investor confidence rose due to financial strength and upcoming clinical milestones in 2026.